Bull Harbor Capital LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 1,779 shares of the medical technology company’s stock, valued at approximately $585,000.
Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the fourth quarter worth $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Buying and Selling
In other news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last three months. 4.60% of the stock is owned by corporate insiders.
Key Stories Impacting Stryker
- Positive Sentiment: Stryker reported second-quarter adjusted earnings of $3.69 per share, ahead of estimates ranging from $3.46 to $3.49 and up from $3.13 a year earlier. Revenue reached $6.59 billion, narrowly exceeding expectations and increasing 9.4% year over year. Stryker Q2 Earnings and Revenues Beat Estimates
- Positive Sentiment: Strong demand for implants and devices used in complex spinal and orthopedic procedures supported the quarterly results, indicating resilient underlying demand for Stryker’s medical technology products. Stryker Beats Quarterly Estimates on Strong Demand
- Positive Sentiment: Management provided full-year 2026 EPS guidance of $14.95 to $15.10, broadly above the current analyst consensus of approximately $14.98, supporting expectations for continued earnings growth.
- Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, implying meaningful upside from recent trading levels and adding a new bullish analyst view. UBS Initiates Stryker Coverage
- Neutral Sentiment: Stryker reported approximately $1.28 billion in profit and said it is making progress recovering from a March cyberattack. However, the recovery remains an operational consideration for investors. Stryker Logs Higher Profit Amid Cyberattack Recovery
- Negative Sentiment: Medical-product companies continue to face potential margin pressure from tariffs and inflation. That concern may temper the market’s reaction to Stryker’s earnings beat, particularly given the stock’s elevated valuation.
Stryker Price Performance
Shares of NYSE:SYK opened at $348.37 on Friday. The firm has a 50 day moving average of $317.08 and a 200-day moving average of $334.98. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $401.99. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $133.55 billion, a PE ratio of 40.32, a PEG ratio of 2.26 and a beta of 0.77.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the company earned $3.13 EPS. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 14.99 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is 40.74%.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the company. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. UBS Group initiated coverage on Stryker in a report on Tuesday. They set a “buy” rating and a $400.00 price target for the company. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Finally, BMO Capital Markets began coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $393.39.
Check Out Our Latest Research Report on SYK
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
- Five stocks we like better than Stryker
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
